Printer Friendly

ApiFix Says Follow-Up Data Shows System Provides "Substantial Reduction" of Scoliosis.

M2 PHARMA-July 13, 2015-ApiFix Says Follow-Up Data Shows System Provides "Substantial Reduction" of Scoliosis

(C)2015 M2 COMMUNICATIONS

US-based medical device maker ApiFix Ltd.'s ApiFix system, which has now been used to correct scoliosis in 50 adolescents since the system was approved for marketing in Europe, continues to demonstrate impressive results at one-to-three years of follow-up with 25 of these patients, the company said on Monday.

ApiFix is a commercial-stage company that has developed the CE-markedApiFix System, a non-fusion minimally invasive treatment alternative for Adolescent Idiopathic Scoliosis.

Scoliosis surgery is the most invasive procedure in spine. The average procedure fuses 10 vertebrae together using 20 screws, resulting in significant and permanent loss of spine mobility.

A clinical study of The ApiFix System led by Prof. Yizhar Floman, M.D. past president of the Israel Spine Society, published this year in the peer-reviewed medical journal Scoliosis concluded that there were many drawbacks to the current gold standard of AIS surgery, which are almost nonexistent with the use of ApiFix.

These drawbacks include the considerable blood loss leading to blood transfusions, neurologic deficit including spinal cord lesions, late infections, pseudoarthrosis, limitation of spinal motion also affecting non-fused levels, back pain and disc degeneration in the non-fused spinal segments.

Almost all of these complications can be avoided by the use of Apifix, the report concluded.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 13, 2015
Words:234
Previous Article:IGI Laboratories introduces diclofenac sodium 1.5 percent topical solution.
Next Article:US FDA Clears Rivanna's Accuro Ultrasound Device.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters